SOLENO THERAPEUTICS

Company snapshot

At Soleno Therapeutics, we believe in the power of science, advocacy, and community. We are honored to stand alongside the Prader-Willi syndrome (PWS) community and are committed to making a meaningful difference in the lives of those impacted by rare diseases. The first and only therapy for the treatment of hyperphagia in #PraderWilliSyndrome received FDA-approval in March 2025. For more informat

• 2 approved product(s) across US/EU regulatory metadata.
• 2 active pipeline program(s) linked via ClinicalTrials.gov.
• 2 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for SOLENO THERAPEUTICS. Not investment advice.

Recent activity

Latest pipeline, patent, and corporate events for SOLENO THERAPEUTICS.

1. Jun 8, 2026 Clinical update

   DCCR (diazoxide choline) extended-release tablets — Phase 2

2. May 23, 2026 Clinical update

   DCCR — Phase 3

View all clinical trial activity →

• What is SOLENO THERAPEUTICS?

  Soleno Therapeutics is a pharma organization headquartered in Redwood City, USA. It trades on NYSE under ticker SLNO. Primary therapeutic focus areas include SH2B1 Deficiency Obesity, Prader-Willi Syndrome. NovaPharmaNews links 2 clinical program(s), 1 drug profile(s), and 0 pate

• Is SOLENO THERAPEUTICS publicly traded?

  Yes. SOLENO THERAPEUTICS is listed with ticker SLNO on NYSE per SEC EDGAR records linked on this profile.

• What drugs does SOLENO THERAPEUTICS develop or market?

  We link 4 drug profile(s) where SOLENO THERAPEUTICS is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/soleno-therapeutics-inc#company-drugs.

• What are the latest developments for SOLENO THERAPEUTICS?

  In the last 12 months our linked public records show 2 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does SOLENO THERAPEUTICS focus on?

  SOLENO THERAPEUTICS focuses on SH2B1 Deficiency Obesity, Prader-Willi Syndrome based on our analysis of their pipeline programs and drug development activities.